Market Overview

UPDATE: Credit Suisse Initiates Jazz Pharmaceuticals with Outperform, $65 PT; Organic and Acquisition Growth Outlook

Related JAZZ
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease
Weekly Wrap-Up Market Forecast Sector Watch SPX Nasdaq FAS BTK SOXX FDN (Marketfy Insights)

Credit Suisse initiates its coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Outperform rating and a price target of $65.

Credit Suisse comments, "We rate JAZZ Outperform because it offers (1) organic growth of the Xyrem franchise, driven by volume growth, pricing power and what we see as a defensible franchise against generics until at least 2020, based on our work with patent counsel; (2) diversification, accretion and cash flows provided by Erwinaze, the key product obtained in the recently announced EUSA acquisition; and (3) a platform for acquisitions created by JAZZ's low tax rate, focused acquisition strategy and execution capabilities."

JAZZ closed at $43.66 on Tuesday.

Latest Ratings for JAZZ

Jul 2015Leerink SwannMaintainsOutperform
Jun 2015UBSMaintainsBuy
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings


Related Articles (JAZZ)

Get Benzinga's Newsletters